Another TRP that could be targeted for its analgesic effects in humans is TRPA1, which is activated by migraine-inducing agents, suggesting that antagonists may help reduce neuropathic pain and migraine [32,89]. The gene discussed is TRPA1; the disease is migraine disorder.